MYX.L

MyCelx Technologies Corporation (DI)
MyCelx Tech. Corp. - Result of AGM
9th July 2024, 13:23
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7284V
MyCelx Technologies Corporation
09 July 2024
 

9 July 2024

 

 

MYCELX Technologies Corporation

 

("MYCELX" or the "Company") (AIM: MYX or MYXR)

 

Result of Annual Meeting

 

 

The Company is pleased to announce that, at its Annual Meeting held on 9 July 2024 at the offices of Canaccord Genuity, 88 Wood Street, London, EC2V 7QR, the resolutions set out in the Notice of Annual Meeting were duly passed on a Poll.

 

Full details of the resolutions passed are set out in the Notice of Meeting which is available on the Company's website www.mycelx.com.

 

Resolutions

For / Discretion

Against

Total

Vote withheld*

Number

%

Number

%

1A To elect Tom Lamb as a Director

 

11,927,255

 

100.00

 

-

 

-

11,927,255

-

1B To elect Connie Mixon as a Director

11,927,255

 

100.00

 

-

 

 

 

-

11,927,255

 

-

1C To elect Haluk (Hal) Alper as a Director

 

11,927,255

 

100.00

-

-

11,927,255

 

-

1D To elect Andre Schnabl as a Director

 

11,927,255

 

100.00

-

-

11,927,255

 

 

-

 

2. Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm

 

11,927,255

 

100.00

-

-

11,927,255

 

-

 

*'Vote withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Bobbie Hilliam

Ana Ercegovic

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

Notes to Editors

Through its revolutionary patented water technology with a mission to reduce the impact of industry on the environment, MYCELX brings its customers material benefits in terms of supporting environmental goals, performance enhancement, cost savings and small footprint. Working beyond any ordinary filtration methods, MYCELX's proprietary technology achieves oil removal to less than one part per million as well as removal of other emerging contaminants in water streams. MYCELX supports its international customers across the oil & gas value chain by ensuring clean water discharge or reuse and in groundwater remediation for industrial and military sites. MYCELX also provides advanced air filtration technology for manufacturing and industrial facilities, effectively removing oil particles and biologicals to maintain continuous and safe air quality levels.

 

For more information, visit www.MYCELX.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGUKUORSRUBRAR]]>
TwitterFacebookLinkedIn